2018年9月6日 - 诺华公司很高兴地宣布,在进行优先审查后,加拿大卫生部已批准Kymriah™(tisagenlecleucel / CTL019)作为第一个嵌合抗原受体T细胞(CAR-T)治疗,以获得加拿大的监管批准。 Kymriah是一种CD19指导的转基因自体T细胞免疫细胞疗法,被批准用于治疗两种威胁生命的癌症,这些癌症的治疗选择有限且历史上的结果...
NEW ORLEANS — For some patients suffering with certain blood cancers, CAR-T therapy can offer the tantalizing chance to end their disease with a single treatment. But the immunotherapy takes time to manufacture, and patients often have to wait weeks to actually receive an infusion once they’...
CD2与其配体CD58之间的相互作用已被证明对CD19 CAR-T细胞杀死肿瘤细胞发挥重要作用,而CD58在淋巴瘤细胞上的表达缺失与接受CD19 CAR-T治疗的患者的耐药性和复发相关。因此,与CD3双特异性相比,通过PIT565共刺激CD2可能会克服T细胞衰竭,增加患者反应的深度和持续时间。 临床前研究结果也表明,与CD3双特异性相比,PIT565...
Novartis, CELLforCURE Partner to Manufacture CAR-T Therapies
CAR T therapies hold the potential for durable, life-changing solutions for patients who have few or no therapeutic options, but only if health authorities and payers agree to reimbursement. Novartis managed to bridge the gap between evidence of efficacy and value in this space with a vari...
2月 28 日,普瑞金生物宣布,其自主研发的靶向 BCMA CAR-T 细胞治疗药物在开展的针对狼疮肾炎的 IIT 临床试验中取得积极结果。该临床试验目前已完成了 6 例患者的入组,以及全部的 6 个月随访, 所有入组患者的病情均为狼疮肾炎 Ⅳ型或Ⅳ + V 型。数据显示,在接受 BCMA CAR-T 细胞治疗后,全部患者在回输 ...
2017年底,其Kymriah CD19 CAR-T疗法终于成为了全球首个获FDA批准的T细胞免疫疗法。当时正值CAR-T火红之际,这个“首批”光环本应意味着灿烂的商业前景。当时诺华负责这一药物开发的正是纳拉森汉,他能荣登第三任CEO的宝座,Kymriah的成功...
Novartis Has Production Hiccup for Kymriah CAR-T Therapy
(anti-BCMA), the first Novartis CAR-T cell therapies developed using this platform. Notably, initial efficacy data show a complete response rate of 73% (95% CI: 44.9, 92.2) at month three for the 15 patients with diffuse large B-cell lymphoma (DLBCL) wh...
(anti-BCMA), the first Novartis CAR-T cell therapies developed using this platform. Notably, initial efficacy data show a complete response rate of 73% (95% CI: 44.9, 92.2) at month three for the 15 patients with diffuse large B-cell lymphoma (DLBCL) who received...